We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lab-Developed Tests Compared with Approved Diagnostics

By LabMedica International staff writers
Posted on 30 Jan 2018
The debate about the role of the government-approved diagnostics in the regulation of laboratory-developed tests (LDTs) has focused attention on the analytical performance of all clinical laboratory testing.

This is particularly important when it comes to detecting common types of cancer mutations such as the B-Raf proto-oncogene, serine/threonine kinase (BRAF), the epidermal growth factor receptor (EGFR), and Kirsten rat sarcoma virus (KRAS) oncology analytes.

A team of scientists from different institutions and led by those at (Brigham and Women's Hospital, Boston, MA, USA) compared the performance of LDTs and US Food and Drug Administration (FDA, Silver Springs, MD, USA) approved companion diagnostics (FDA-CDs), in proficiency testing (PT) provided by the College of American Pathologists Molecular Oncology Committee (CAP, Northfield, IL, USA). More...
The team analyzed the performance of 6,897 tests from laboratories participating in the CAP Proficiency Testing (PT) for BRAF, EGFR, and KRAS, oncology analytes used often by both LDTs and FDA-CDxs. A total of 6,897 PT responses were included: BRAF (n = 2,524; 14 PT samples), EGFR (n = 2,216; 11 PT samples), and KRAS (n = 2,157, 10 PT samples). FDA ompanion diagnostics and LDTs are compared for both accuracy and preanalytic practices of the laboratories.

Using CAP standards, they compared accuracy and preanalytic practices of the laboratories and found that both types of tests exceeded 97% accuracy across the three cancer genes. In another important finding, the scientists discovered that at least 60% of the participating laboratories had adapted an FDA-CDx test to the point that it changed the classification to an LDT. According to the specialists, laboratories did this to “allow for a greater breadth of sample types, minimum tumor content, and instrumentation.” From a regulatory perspective, the data suggest that there’s not as much of a difference between FDA-CDxs and LDTs as previously thought. The high marks on LDT proficiency are significant, given the scrutiny these tests have experienced over their reliability. FDA for some time has advocated for increased oversight of LDTs, claiming that they should be regulated as medical devices.

Annette S. Kim, MD, PhD, an associate pathologist and first author of the study, said, “These modifications appear to be driven by the exigencies of real day-to-day clinical practice that requires altering the assays to meet the needs of a variety of clinical situations that may not be accommodated by the FDA-approved protocol.” The study was published originally published online on December 14, 2017, in the journal JAMA Oncology.

Related Links:
Brigham and Women's Hospital
US Food and Drug Administration
College of American Pathologists

New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.